Rigel Pharmaceuticals, Incorporated

Theravance Respiratory Company, LLC

Merck Sharp + Dohme Corp.

Theravance, Inc.

Rose Yen

Yan Chen

Rajinder Paul Singh

Vanessa Taylor

Hui Li

Thilo J Heckrodt

Kin Tso

Darren J McMurtrie

Adam D Hughes

Eric L Stangeland

John R Jacobsen

Ryan Kelley

Melissa Fleury

Pingyu Ding

Richard D Wilson

Daniel Byun

Jack Maung

Sacha Holland

Donald G Payan

Esteban Masuda

Jing Zhang

Matthew Duncton

Rao Kolluri

Salvador Alvarez

Simon Shaw

Jiaxin Yu

Yeon-Hee Lim

James Patrick Roane

Jillian R Sanzone

Samantha E Shockley

Victor W Mak

Cedric Lorenz Hugelshofer

Darren John Mcmurtrie

Sambaiah Thota

Jianming Bao

Fa-Xiang Ding

Eric Strangeland

Darren Mcmurtrie

Rajinder Singh

Richard Wilson

Sambaiah Thhota

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Diacylglyceride O-acyltransferase 2 inhibitors

Disclosed are novel benzazole compounds and compositions comprising the compounds. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Benzazole compounds and methods for making and using the compounds

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

IRAK inhibitors and method for making and using

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Amide compounds and method for making and using

Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; Ris selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and heteroaryl; and Rand Rare independently selected from hydrogen and (C1-C6)alkyl. Disclosed compounds may have an IRAK4 ICof from 0.003 &#x3bc;M to 3.7 &#x3bc;M; a TAK1 ICof from 0.008 &#x3bc;M to 132 &#x3bc;M; and/or an IRAK4/TAK1 selectivity of from 1 to 450. Particular compounds may have an IRAK4/TAK1 selectivity of from 100 to 500. Disclosed compositions may be formulated as pharmaceutical compositions. A method for using the compounds and/or compositions also are disclosed. The method may comprise administering to a subject an effective amount of a compound within the scope of the present invention, particularly to selectively inhibit IRAK 1 and/or IRAK4 over TAK1.

2,4-diamino-pyrimidine compounds and method for making and using the compounds

Pyrazole compounds and methods for making and using the compounds

Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.

Compositions and methods for inhibition of the JAK pathway

Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors according to Formula 1, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Kinase inhibitors and methods for making and using

The invention relates to a pharmaceutical composition comprising an isotonic aqueous solution comprising a compound of formula I: or a pharmaceutically acceptable salt thereof.

Diamide compounds having muscarinic receptor antagonist and &#x3b2;2 adrenergic receptor agonist activity

Growing community of inventors

San Francisco, CA, United States of America

Rose Yen